vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $182.4M, roughly 1.9× Climb Global Solutions, Inc.). HAEMONETICS CORP runs the higher net margin — 13.2% vs 1.8%, a 11.4% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (32.1% vs -2.7%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (40.7% CAGR vs 0.4%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CLMB vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $339.0M |
| Net Profit | $3.3M | $44.7M |
| Gross Margin | 14.5% | 59.7% |
| Operating Margin | 2.1% | 19.9% |
| Net Margin | 1.8% | 13.2% |
| Revenue YoY | 32.1% | -2.7% |
| Net Profit YoY | -9.5% | 19.3% |
| EPS (diluted) | $0.18 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $339.0M | ||
| Q3 25 | $161.3M | $327.3M | ||
| Q2 25 | $159.3M | $321.4M | ||
| Q1 25 | $138.0M | $330.6M | ||
| Q4 24 | $161.8M | $348.5M | ||
| Q3 24 | $119.3M | $345.5M | ||
| Q2 24 | $92.1M | $336.2M |
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $44.7M | ||
| Q3 25 | $4.7M | $38.7M | ||
| Q2 25 | $6.0M | $34.0M | ||
| Q1 25 | $3.7M | $58.0M | ||
| Q4 24 | $7.0M | $37.5M | ||
| Q3 24 | $5.5M | $33.8M | ||
| Q2 24 | $3.4M | $38.4M |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 59.7% | ||
| Q3 25 | 15.9% | 59.5% | ||
| Q2 25 | 16.5% | 59.8% | ||
| Q1 25 | 16.9% | 58.4% | ||
| Q4 24 | 19.3% | 55.5% | ||
| Q3 24 | 20.3% | 54.2% | ||
| Q2 24 | 20.2% | 52.0% |
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | 19.9% | ||
| Q3 25 | 4.3% | 17.9% | ||
| Q2 25 | 5.0% | 16.8% | ||
| Q1 25 | 3.5% | 21.6% | ||
| Q4 24 | 7.2% | 16.9% | ||
| Q3 24 | 7.1% | 15.0% | ||
| Q2 24 | 4.6% | 11.8% |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | 13.2% | ||
| Q3 25 | 2.9% | 11.8% | ||
| Q2 25 | 3.7% | 10.6% | ||
| Q1 25 | 2.7% | 17.5% | ||
| Q4 24 | 4.3% | 10.8% | ||
| Q3 24 | 4.6% | 9.8% | ||
| Q2 24 | 3.7% | 11.4% |
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $0.95 | ||
| Q3 25 | $1.02 | $0.81 | ||
| Q2 25 | $1.30 | $0.70 | ||
| Q1 25 | $0.81 | $1.17 | ||
| Q4 24 | $1.52 | $0.74 | ||
| Q3 24 | $1.19 | $0.66 | ||
| Q2 24 | $0.75 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $118.4M | $911.5M |
| Total Assets | $458.8M | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $363.4M | ||
| Q3 25 | $49.8M | $296.4M | ||
| Q2 25 | $28.6M | $292.9M | ||
| Q1 25 | $32.5M | $306.8M | ||
| Q4 24 | $29.8M | $320.8M | ||
| Q3 24 | $22.1M | $299.3M | ||
| Q2 24 | $48.4M | $344.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $911.5M | ||
| Q3 25 | $109.3M | $849.2M | ||
| Q2 25 | $105.2M | $882.3M | ||
| Q1 25 | $95.6M | $820.8M | ||
| Q4 24 | $90.6M | $906.9M | ||
| Q3 24 | $87.7M | $878.9M | ||
| Q2 24 | $79.8M | $905.4M |
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $2.5B | ||
| Q3 25 | $376.1M | $2.4B | ||
| Q2 25 | $420.7M | $2.5B | ||
| Q1 25 | $370.1M | $2.5B | ||
| Q4 24 | $469.2M | $2.5B | ||
| Q3 24 | $371.9M | $2.5B | ||
| Q2 24 | $302.8M | $2.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $93.6M |
| Free Cash FlowOCF − Capex | — | $87.2M |
| FCF MarginFCF / Revenue | — | 25.7% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $93.6M | ||
| Q3 25 | $22.2M | $111.3M | ||
| Q2 25 | $-2.2M | $17.4M | ||
| Q1 25 | $8.5M | $116.6M | ||
| Q4 24 | $16.0M | $43.8M | ||
| Q3 24 | $-3.6M | $48.8M | ||
| Q2 24 | $7.3M | $-27.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | 2.09× | ||
| Q3 25 | 4.73× | 2.88× | ||
| Q2 25 | -0.37× | 0.51× | ||
| Q1 25 | 2.30× | 2.01× | ||
| Q4 24 | 2.29× | 1.17× | ||
| Q3 24 | -0.66× | 1.44× | ||
| Q2 24 | 2.13× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLMB
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
